S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO® (ivacaftor) in Canada for Eligible People with Cystic Fibrosis|
|Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014|
|CF Industries Holdings, Inc. Reports Second Quarter Net Earnings of $312.6 Million (2014/8/6)|
|CF Industries Holdings, Inc. Announces Dates for Second Quarter 2014 Results and Conference Call (2014/7/24)|
|CF Industries Resumes Production at Its Woodward, Oklahoma, Nitrogen Complex (2014/7/16)|
|CF Industries Sells Carbon Credits to Chevrolet and Donates Proceeds to FFA (2014/7/16)|
|Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation|
|Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations|
|Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation|
|Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations|
Click above to view more mutual fund data and stats for cf - CF Industries Holdings Inc.